Anonymous ID: e7ff8e Dec. 3, 2023, 7:18 a.m. No.20019090   ๐Ÿ—„๏ธ.is ๐Ÿ”—kun

>>20019089

>Venezuela does not recognize the International Court of Justice's jurisdiction in the decades-old dispute over the Essequibo region and is expected to press ahead with the referendum regardless of what its judges decide.

Anonymous ID: e7ff8e Dec. 3, 2023, 7:22 a.m. No.20019118   ๐Ÿ—„๏ธ.is ๐Ÿ”—kun

https://en.wikipedia.org/wiki/Guayana_Esequiba

The boundary dispute was inherited from the colonial powers (Spain in the case of Venezuela, and the Netherlands and the United Kingdom in the case of Guyana) and has been complicated by the independence of Guyana from the United Kingdom in 1966.

Anonymous ID: e7ff8e Dec. 3, 2023, 7:48 a.m. No.20019219   ๐Ÿ—„๏ธ.is ๐Ÿ”—kun   >>9242

https://www.wsj.com/business/the-storm-brewing-inside-elon-musks-mind-gets-out-b6104a94

The Storm Brewing Inside Elon Muskโ€™s Mind Gets Out

His giant F-bombs overshadowed his Israel trip and Cybertruck launch

Anonymous ID: e7ff8e Dec. 3, 2023, 7:50 a.m. No.20019229   ๐Ÿ—„๏ธ.is ๐Ÿ”—kun

https://www.wsj.com/tech/biotech/gene-editing-changing-medicine-9cc02c7e

Gene Editing Will Change Medicineโ€”and Maybe Health Investing Too

The first treatment based on Crispr technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors

The groundbreaking gene-editing technology known as Crispr, which acts like a molecular pair of scissors that can be used to cut and modify a DNA sequence, has moved rather quickly from the pages of scientific journals to the medical setting. Earlier this month, about three years after Jennifer Doudna and Emmanuelle Charpentier won the Nobel Prize in Chemistry for describing how bacteriaโ€™s immune system could be used as a tool to edit genes, regulators in the U.K. approved the first Crispr-based treatment for sickle cell disease and beta-thalassemia patients. The treatment, from Vertex Pharmaceuticals, could be approved by the U.S. Food and Drug Administration early next month for sickle cell patients.